In keeping with a differential spatial genome organization in cancers above and below the treatment threshold, we previously found MMP9 to reposition in 20% of low Gleason score cancers compared to 82% of intermediate/high Gleason score cancers (Leshner et al., 2016). Here, MMP9 is linked to cancer.